NPS Seeks Development Partners For Preos And Teduglutide, Reduces Force

NPS Pharmaceuticals is reducing its workforce and consolidating operations while continuing to advance two pipeline candidates - the osteoporosis agent Preos and the gastrointestinal treatment teduglutide -following a review of its financial situation